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ABSTRACT
MicroRNAs (miRNAs) are small regulatory non-coding RNAs for which altered 
expression in cancers can serve as potential biomarkers for diseases. We here 
investigated whether circulating miRNAs can serve as biomarkers for predicting 
post-operational recurrence of oral squamous cell carcinoma (OSCC) in patients. 
Plasma samples from 8 Danish OSCC patients were collected before, and one year 
after surgical operation, as well as from 3 Danish healthy controls and subjected to 
miRNA profiling by next generation sequencing. Disease recurrence did not occur 
in the 8 patients when the post-operative plasma samples were collected. Based on 
the sequencing data, three up-regulated miRNAs (miR-148a-3p, miR-26a-5p and miR-
21-5p) and three down-regulated miRNAs (miR-375, miR-92b-3p and miR-486-5p) in 
the OSCC samples compared to healthy controls were selected for qRT-PCR validation 
in a Chinese cohort of 20 plasma samples collected before, and 9-12 months after 
surgical operation, and 18 healthy controls. Disease recurrence had occurred in 
8 out of the 20 Chinese patients at the time their post-operative plasma samples 
were collected. The results of qRT-PCR showed that down-regulation of miR-486-5p, 
miR-375 and miR-92b-3p were highly associated with OSCC recurrence. This study 
indicates that the plasma miRNA profile is altered in OSCC during its progression and 
can be used to monitor the likelihood of OSCC recurrence in patients after surgery.
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is one of 
the most common human cancers worldwide. Tobacco 
and alcohol are the most important causative mutagens of 
OSCC, as well as infection with high-risk types of human 
papillomavirus (HPV) [1]. The number of OSCC patients 
increases and it was estimated that numbers of 263,900 
diagnosed cases and 128,000 deaths in 2008 raised 
approximately to 300,400 and 145,400, respectively, in 
2012 [2, 3]. Although several types of treatments have 
been used for OSCC, the five-year survival rate is only 
about 50% due to frequent metastases to regional lymph 
nodes [4].
MicroRNAs (miRNAs) are small non-coding 
RNAs (~22nt) that regulate gene expression by repressing 
mRNA translation or destabilizing the mRNA [5, 6]. 
MiRNA expression is usually dramatically altered in 
cancer, and it has been proven that miRNAs can serve as 
diagnostic and therapeutic biomarkers for various cancers 
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[7, 8]. Both tumor-suppressive and oncogenic miRNAs 
whose expressions are either down- or up-regulated in 
cancer have been discovered [9, 10]. Cell-free miRNAs, 
circulating in body fluids such as plasma, serum, urine 
and saliva, can serve as minimally invasive diagnostic and 
prognostic biomarkers for cancers [11]. Next generation 
sequencing (NGS) of such RNAs has been used to identify 
specific changes in circulating miRNAs in lung-, breast- 
and nasopharyngeal cancer [12–14].
Recent reports have also identified cancer specific 
miRNA signatures in OSCC cell lines and tissue samples, 
such as down-regulation of miR-137, miR-193a, miR-
375, miR-145 and miR-222 and up-regulation of miR-
127, miR-21 and miR-10b [15–21]. However studies on 
circulating miRNAs in OSCC are limited. Using qRT-
PCR, it was shown that miR-31 was up-regulated in OSCC 
plasma compared to healthy plasma, while miR-125a and 
miR-200a were repressed in the saliva of OSCC patients 
when compared to healthy control subjects [22, 23]. In 
head and neck squamous cell carcinoma (HNSCC), the 
signatures of small non-coding RNAs in serum samples of 
patients and healthy donors were characterized by NGS, 
and it was found that miRNAs, 5’tRNA halves and 5’ or 
3’yRNA fragments were significantly associated with 
HNSCC [24]. Radio (chemo) therapy responsive miRNAs 
were identified by microarray screening of miRNAs in 
HNSCC patient plasma before and after therapy, and 
miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p 
and miR-574-3p were identified as the most promising 
prognostic marker to monitor the therapy [25]. But there 
are no reports on the NGS profiling on OSCC recurrence-
associated miRNAs in plasma yet.
Our aim in this study is to characterize dysregulation 
of plasma miRNAs in OSCC and OSCC recurrence after 
surgery. Plasma from Danish OSCC patients without 
recurrence was collected before and after surgical 
operation, as well as from Danish healthy control, and 
the miRNAs were profiled by NGS. Three OSCC down-
regulated and three up-regulated miRNAs were selected 
for validation by qRT–PCR in a Chinese cohort of plasma 
samples including both of patient plasma with and without 
OSCC recurrence after surgery and healthy controls. In 
this study, the differential expressions of miR-486-5p, 
miR-375 and miR-92b-3p in pre- and post-operative 
paired plasma samples were found to be associated with 
the risk of OSCC recurrence 9-12 months after surgery.
RESULTS
Profiling of miRNA and other small RNAs 
in plasma
Small RNA deep sequencing was performed on 
a Danish cohort of pre-operative and post-operative 
plasma collected from 8 OSCC patients and 3 healthy 
controls. After the removal of low-quality reads and 
adaptor sequences, the mean yield of clean reads was 
5.15 million (range: 2.83 million – 8.47 million). Length 
distribution analysis of all samples revealed an expected 
peak at 20 – 24 nts, consistent with the size of miRNAs, 
while there were another two peaks at 27nts and 31-33 
nts (Supplementary Figure 1A). Annotation analysis of all 
samples showed that 40% of the reads were annotated as 
human miRNAs, 35% as Y RNAs fragment and 9% as 
mRNA (Supplementary Figure 1B, Supplementary Table 
5). Y RNA produces fragments of 27 nts and 31-33 nts 
and accounts for the longer peaks in the length distribution 
analysis (Supplementary Figure 1A). Y RNA fragments 
sequenced in our data were mainly from the 5’-end of Y4 
mapping to human genome GRCh37/hg19 Chromosome 
3: 156,871,337-156,871,429.
There were 1156, 1066 and 810 known miRNAs 
annotated in the pre-operative, post-operative and 
healthy samples, respectively. Most of the miRNAs (745 
miRNAs) were detected in all samples, while 161, 81 
and 11 miRNAs were pre-operative, post-operative and 
healthy sample specific, respectively (Figure 1A). All 
sample specific miRNAs were lowly expressed (RPM 
< 50) suggesting that these are of limited biological 
meaning. Hence, in this study, all miRNAs of interest are 
from the set detected in all samples. Principal component 
analysis (PCA) was conducted for the 100 most abundant 
miRNAs (Figure 1B). MiRNA profiles from healthy and 
pre-operative patient samples formed discrete groups 
while post-operative overlapped with both other groups. 
A confounding this analysis was the fact that pre- and 
post-operative samples were taken from the same patients. 
Therefore, paired samples will tend to be close together 
due to the identical genetic background of the samples, 
counteracting functional grouping. However, we did 
observe a clear shift in half of the post-operative samples 
from patients without recurrence, which cluster with 
healthy samples, indicating that miRNA expression is 
related to patient’s outcome.
Differential expressions of plasma miRNAs 
in OSCC
We analyzed the differential expression of miRNAs 
by comparing the miRNA expression of pre-operative 
plasma samples to that of paired post-operative plasma 
samples and healthy control plasma samples. There were 
32 miRNAs significantly dysregulated with p-value < 0.05 
including 31 up-regulated and 1 down-regulated in pre-
operative samples compared to post-operative and healthy 
samples (Supplementary Table 6). Three significantly 
up-regulated miRNAs (miR-26a-5p, miR-148a-3p and 
miR-21-5p) and one significantly down-regulated miRNA 
(miR-486-5p) with p-value < 0.05 were chosen to do 
further validation (Supplementary Table 7).
MiR-375 was also chosen as a candidate due to 
its decreased expression in OSCC tumors compared 
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to adjacent normal tissue and healthy epithelium in our 
previous study [16]. In the present study, this miRNA 
was up-regulated in post-operative samples compared 
to pre-operative samples in 6 out of 8 patients, although 
the up-regulation was not significant (p-value = 0.19) 
(Supplementary Table 7). In addition, miR-92b-3p was 
chosen due to its significantly increased expression 
in post-operative samples compared to pre-operative 
samples (Supplementary Table 7). Compared to healthy 
group, the expression of both miR-375 and miR-92b-3p 
were decreased in pre-operative group (Supplementary 
Table 7).
Validation of dysregulated miRNA candidates in 
an independent cohort of plasma samples
The levels of the six selected miRNAs were further 
validated in a Chinese cohort of pre- and post- paired 
OSCC plasma samples and healthy controls by qRT–PCR. 
The expression of miR-486-5p in post-operative samples 
was elevated in 16 out of 20 patients (80%) compared to 
that in pre-operative samples with statistical significance 
(p-value < 0.01) (Figure 2A). Such significantly higher 
expression of miR-486-5p was also shown in healthy 
samples while comparing to that in pre-operative samples 
(p-value < 0.05) (Figure 2B). Furthermore, there was 
no significant difference between post-operative and 
healthy samples (p-value > 0.05) (Figure 2B), implying 
the recovery of miR-486-5p expression level to healthy 
conditions after surgery. Compared to the expression 
in pre-operative samples, miR-375 and miR-92b-3p 
recovered in paired post-operative samples in 17 patients 
(17 out of 20, 85%) (Figure 2C) and in 15 patients (15 out 
of 20; 75%) (Figure 2E), respectively. The up-regulation 
of these two miRNAs in post-operative samples compared 
to paired pre-operative samples was significant with 
p-value < 0.01, whereas the higher expression of these 
two miRNA in healthy samples compared to pre-operative 
samples were non-significant (p-value > 0.05) (Figure 2D 
and 2F). No significant difference was seen for the three 
oncogenic miRNA candidates (miR-148a-3p, miR-26a-5p 
and miR-21-5p) when quantified by qRT–PCR (Figure 
2G–2L).
Plasma miRNAs as prognostic biomarkers of 
OSCC recurrence
OSCC had recurred in 8 out of the 20 patients in the 
Chinese cohort at the time their post-operative samples 
were collected for qPCR validation. The down-regulation 
of miR-486-5p in pre-operative samples compared to 
healthy samples were significant with p-value < 0.05 in 
the patient groups both with and without OSCC recurrence 
(Figure 3B and 3D). For the non-recurrence group, the 
elevation of the miR-486-5p in post-operative samples 
compared to pre-operative samples was observed in 11 
out of 12 cases (92%) with a p-value < 0.01 (Figure 3A). 
However, for the OSCC recurrence group, miR-486-5p 
elevation was seen only in 3 out of 8 (37.5%) with no 
significance (Figure 3C). In the non-recurrence group, 
miR-375 and miR-92b-3p were significantly increased in 
post-operative samples compared to pre-operative samples 
(Figure 4A and 4C). There were no significant changes 
for these two miRNAs between pre-operative and post-
Figure 1: Expression Analysis of miRNAs. A. The Venn chart of annotated known miRNAs in the Pre-operative, Post-operative and 
Healthy groups. B. PCA analysis of the top 100 high expressed miRNAs in the Pre-operative, Post-operative and Healthy groups. Colored 
circles indicate 0.75 confidence for the three groups.
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Figure 2: The expression of miRNAs studied by qRT–PCR. The differential expressions of A. miR-486-5p, C. miR-375, E. 
miR-92b-3p, G. miR-148a-3p, I. miR-26a-5p and K. miR-21-5p in pre-operative and paired post-operative plasma samples in different 
patients. The differential expressions of B. miR-486-5p, D. miR-375, F. miR-92b-3p, H. miR-148a-3p, J. miR-26a-5p and L. miR-21-5p in 
pre-operation, post-operation and healthy control groups. The upper and lower limits of the boxes and the lines inside the boxes indicate the 
75th and 25th percentiles and the median, respectively; the upper and the lower horizontal bars denote the max and min values, respectively. 
The expression of miRNAs was normalized to Spike-in. P-value between pre-operation and post-operation was calculated by paired t-test; 
P-values between pre-operation and healthy control, post-operation and healthy control, were calculated by two sample t-test. **: p-value 
< 0.01; *: p-value < 0.05.
Oncotarget8210www.impactjournals.com/oncotarget
operative samples in recurrence group (Figure 4B and 4D). 
In summary, our data indicates that the expression level 
of miR-486-5p, miR-375 and miR-92b-3p are associated 
with OSCC recurrence 9-12 months after surgery. For the 
oncogenic miRNAs, the changes between pre-operative 
and post-operative samples were insignificant in both in 
the non-OSCC recurrence group and OSCC recurrence 
group (data not shown).
DISCUSSION
In this study, we aimed to select plasma miRNA 
biomarkers for the diagnosis of OSCC and for monitoring 
the risk of recurrence. Circulating small RNAs in plasma 
were profiled by NGS in plasma samples from OSCC 
patient pre- and paired post-operation and from healthy 
controls. To our knowledge, this is the first report on small 
RNA profiling by NGS in paired pre- and post-operative 
plasma samples in OSCC.
QRT-PCR validated the NGS finding and indicated 
that miR-486-5p could serve as a potentially diagnostic 
biomarker for OSCC, due to its significantly lower 
expression in pre-operative samples compared to healthy 
ones and the increased expression close to the healthy 
level in post-operative samples. Moreover, miR-486-
5p was highly associated with OSCC recurrence 9-12 
months after surgery, since expression of miR-486-5p 
was not significantly increased in post-operative samples 
compared to the expression in pre-operative samples in 
patients with OSCC recurrence but the increase was 
significant in patients without OSCC recurrence. These 
findings suggest that miR-486-5p could act as a biomarker 
to monitor OSCC recurrence after surgery. The tumor-
suppression activity of miR-486-5p has also been detected 
Figure 3: The expression of miR-486-5p in non-OSCC recurrence and OSCC recurrence groups studied by qRT–PCR. 
The differential expression of miR-486-5p between pre-operative and paired post-operative plasma in A. non-OSCC recurrence group and 
C. OSCC recurrence group. The differential expression of miR-486-5p in B. patient group without OSCC recurrence and healthy control 
group, and in D. patient group with OSCC recurrence and healthy control group. The upper and lower limits of the boxes and the lines inside 
the boxes indicated the 75th and 25th percentiles and the median, respectively; the upper and the lower horizontal bars denote the max and 
min values, respectively. The expression of miR-486-5p was normalized to the spike-in. P-value between pre-operation and post-operation 
was calculated by paired t-test; P-values between pre-operation and healthy control, post-operative and healthy control, were calculated by 
two sample t-test. **: p-value < 0.01; *: p-value < 0.05.
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in other types of cancer. It was found that miR-486-5p was 
repressed in breast cancer tissue and cell lines, where it 
was validated to target the oncogene PIM-1 [26]. In lung 
cancer, miR-486-5p was identified as a tumor-suppressor 
by down-regulating protumorigenic ARHGAP5 and insulin 
growth factor signaling, and its down-regulation was also 
validated in plasma samples [27–29]. In gastric cancer, the 
down-regulation of miR-486-5p was confirmed in tissue 
and cell lines and OLFM4 was identified as the target [30]. 
MiR-486-5p has previously been reported to be down-
regulated in OSCC tissue [31], however, there is no report 
detecting circulating miR-486-5p in OSCC. Based on our 
study we suggest circulating miR-486-5p be a biomarker 
for OSCC diagnosis and OSCC recurrence after surgery.
From the qRT-PCR validation data, miR-375 was 
also significantly up-regulated in post-operative samples 
compared to pre-operative samples. This is in agreement 
with the NGS data where miR-375 was up-regulated 
in post-operative samples compared to pre-operative 
samples in 6 out of 8 patients although the elevation 
was not significant. MiR-375 also expressed higher in 
healthy samples compared to pre-operative samples in 
both sequencing data and qPCR, though not significantly. 
MiR-375 expression level was also associated with 
OSCC recurrence due to its significant increase in post-
operative samples in patients without OSCC recurrence 
and insignificant change in patients with OSCC recurrence 
in qRT-PCR validation. In the previous report from our 
lab, the down-regulation of miR-375 was documented in 
tissue, saliva and oral rinse between OSCC patient and 
healthy people [16]. Hence, miR-375 is reproducibly 
repressed in OSCC and can also help monitoring OSCC 
recurrence after surgery
Also for miR-92b-3p, significantly higher 
expression was observed in post-operative compared to 
pre-operative samples according to sequencing data and 
qPCR validation. Moreover, miR-92b-3p expression level 
was also significantly increased in post-operative samples 
Figure 4: The expressions of miR-375 and miR-92b-3p in non-OSCC recurrence and OSCC recurrence groups studied 
by qRT–PCR. The expression pattern of miR-375 in pre-operative and post-operative plasma samples in the patients A. without OSCC 
recurrence and B. with OSCC recurrence. The expression pattern of miR-92b-3p in pre-operative and post-operative plasma samples in the 
patients C. without OSCC recurrence and D. with OSCC recurrence. The expression of miRNAs was normalized to the spike-in. P-values 
between pre-operation and post-operation were calculated by paired t-test. **: p-value < 0.01; *: p-value < 0.05.
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in patients without OSCC recurrence and insignificant 
change in patients with OSCC recurrence in qRT-PCR 
validation.
The discrepancy we observed in the expression of 
miR-148a-3p, miR-26a-5p and miR-21-5p between the 
NGS data of the Danish cohort and the qPCR result of 
Chinese cohort may be explained by known biases in the 
two methods or by racial differences.
In conclusion: circulating miR-486-5p was 
identified as a significantly tumor-suppressive miRNA in 
OSCC. Relative levels of miR-486-5p, miR-375 and miR-
92b-3p in plasma were risk-indicators of OSCC recurrence 
9-12 months after surgery.
MATERIALS AND METHODS
Patients and plasma samples
Plasma samples from two patient cohorts were 
obtained in this study. The initial NGS based observations 
were performed in one Danish cohort and qRT-PCR based 
validation of the findings were performed in one Chinese 
cohort.
The plasma samples of OSCC patients and healthy 
volunteers used for NGS analysis were obtained from 
Odense University Hospital, Denmark. Informed written 
consent was obtained individually and the Ethics Committee 
in Region Middle Jutland approved the research according 
to Danish legislation (M-20110028). Blood was collected 
from 3 healthy adult volunteers and 8 OSCC patients. 
Patient plasma was collected twice, before and one year 
after the surgical operation. There was no OSCC recurrence 
when the post-operative plasma samples were collected. 
The median age of patients was 70 years (range 57-90) 
and included five males and three females (Supplementary 
Table 1). The median age of healthy volunteers was 64 
years (range from 62-68) and consisted of two males and 
one female (Supplementary Table 2). Blood (4 ml) was 
drawn by standard antecubital vein phlebotomy with EDTA 
tubes and centrifuged at 10,000 rpm for 10 min at 4°C. The 
plasma supernatant was separated from blood cells and 
frozen at −80°C.
The plasma samples from OSCC patients and 
healthy volunteers used for qRT-PCR were obtained from 
Beijing Stomatological Hospital, China. Written informed 
consent was obtained from all participants, and the 
study was approved by the Ethics Committee of Beijing 
Stomatological Hospital. Blood was collected from 18 
healthy adult volunteers and 20 OSCC patients. Patient 
plasma was collected twice, before and 9-12 months after 
surgery. Eight patients had experienced OSCC recurrence 
when the post-operative plasma was collected. The median 
age of patients was 63 years (range 44-74) and included 14 
males and 6 females (Supplementary Table 3). The median 
age of the healthy volunteers was 53 years (range from 37-
73) and included 7 males and 11 females (Supplementary 
Table 4). Plasma was collected as described above.
Small RNA library construction and sequencing
RNA was isolated from 1 ml of plasma and eluted 
in 10 ul of RNase-free water using the miRNeasy Serum/
Plasma Kit (Qiagen) according to the manufacturer’s 
protocol. RNA (5 ul) from each sample was used to construct 
sequencing libraries with the Illumina TruSeq Small RNA 
Sample Prep Kit (Illumina). In order to produce viable 
libraries from the low RNA content plasma samples, while 
avoiding extensive adaptor dimers formation, all kit reagents 
were reduced by half, and the library preparation PCR step 
was performed with 15 cycles. The size and purity of the 
purified cDNA libraries was validated on a 2100 Bioanalyzer 
High Sensitivity DNA chip (Agilent) and the concentration 
was quantified using KAPA Library Quantification Kit 
(KAPA biosystems). The libraries were pooled as required 
and sequenced on the Illumina HiSeq 2000 instrument by 
Beijing Genomics Institute (BGI).
Sequencing data analysis
Raw reads were filtered with FASTX-Toolkit to 
trim away low-quality reads and cut adapt to remove 
adaptor sequences. The clean reads were mapped to a 
list of datasets using Bowtie. First, reads were mapped 
to human miRNAs, and other miRNAs from miRBase 
v20 allowing zero mismatches. Then the unmapped 
reads were mapped against other relevant small RNA 
datasets: piRNA, tRNA, snRNA, snoRNA and Y RNA 
allowing one mismatch. To assess degradation, the 
remaining unmapped reads were mapped to long RNA 
datasets: rRNA, lincRNA, other RNAs from Rfam 
and mRNA. Finally, to detect bacterial RNA content 
the reads not mapping to any of the prior datasets 
were mapped to the complete annotated human oral 
microbiome (http://www.homd.org/). The expressions 
of miRNAs were normalized using the formula: miRNA 
normalized expression = (miRNA counts / the total 
counts of all mapped miRNAs)*106. The 100 highest 
expressed miRNAs were log2 transformed, and principal 
component analysis (PCA) was performed using the R 
function princomp. PCA was plotted with qplot from the 
ggplot2 R package.
Calculation of fold change and p-value was 
performed after the normalization scheme described 
above. Fold change between pre- and post-operative paired 
sample was determined as: log2 (miRNA expression of 
pre-operative sample / miRNA expression of paired post-
operative sample), and the p-value was calculated with a 
paired t-test. Fold change between the pre-operative patient 
group and the healthy control group was determined as: 
log2 (expression median of pre-operative patient group / 
expression median of healthy control group), and p-value 
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was calculated using t-test. Fold change between the post-
operative patient group and the healthy control group was 
determined as: log2 (expression median of post-operative 
patient group / expression median of healthy control 
group), and p-value was calculated using a t-test. MiRNAs 
were deemed significantly dysregulated at p-value <0.05 
and Abs (fold change) ≥1.
QRT-PCR validation
Validation of miRNA differential expression was 
performed using qRT-PCR on plasma samples from 
persons unrelated to those examined using NGS. RNA 
was isolated from 200 ul of plasma by miRCURY RNA 
Isolation Kits-Biofluids (Exiqon) and reverse transcribed 
by Universal cDNA Synthesis kit II (Exiqon). 7.5×10-2  
fmol Serum/Plasma Spike-in Control (Qiagen) was added to 
each sample according to the manufacturer’s protocol. The 
cDNA samples were added into Pick-&-Mix microRNA 
PCR Panels (Exiqon), which were pre-loaded with LNA 
PCR primers of miRNAs and inter-plate calibrator (UniSp3). 
The panels were run on a Stratagene Mx3005p machine. The 
expression of miRNAs was normalized to the Spike-in.
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